Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 18 Sep 2025
A novel targeted radiation approach for a rare form of malignant tumor—the solitary fibrous tumor (SFT)—has shown significant success, achieving a near-complete response in three patients. The therapy significantly reduced ...
Read Full NewsClinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.
Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.
Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.
The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.
1.
Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.
2.
Childhood cancer survivors face new health problems later in life, study shows
3.
A new blood test greatly increases the ability to detect cancer.
4.
Use of marijuana and alcohol simultaneously is associated with worse outcomes.
5.
Exercise can counter detrimental effects of cancer treatment, review suggests
1.
Breast Cancer Secrets: AI-Powered Precision Medicine
2.
Deterministic Reprogramming of Neutrophils within Tumors: A New Frontier in Cancer Research
3.
Examining Serum Osmolality: What It Is And How To Test For It
4.
Unlocking the Secrets of Oral Cancer Staging: A New Approach to Early Detection
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
5.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge